Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

NCT02835508 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-56021927 60 Milligram
DRUG: JNJ-56021927 120 Milligram
DRUG: JNJ-56021927 240 Milligram

Sponsor

Janssen Pharmaceutical K.K.